- Jan 28
Genetic ancestry provides important context for understanding global diversity in childhood leukemia
St. Jude Children's Research Hospital scientists have shown that addressing racial disparities in acute lymphoblastic leukemia should include considering how genetic ancestry affects biology and prognosis. Read more: https://www.prnewswire.com/news-releases/genetic-ancestry-provides-important-context-for-understanding-global-diversity-in-childhood-leukemia-301470205.html
- Jan 27
Nanoparticle-formulated drug combination is effective in medulloblastoma, a pediatric brain tumor
Researchers have demonstrated that a novel combination of two drugs that act as targeted inhibitors, delivered in a nanoparticle formulation, extend the survival of mice with medulloblastoma. The research team believes this laboratory success could be translated into a less toxic treatment for medulloblastoma, the most common malignant pediatric brain tumor. Read more: https://www.sciencedaily.com/releases/2022/01/220126144237.htm
- Jan 24
‘Welcome to our world’: families of children with cancer say the pandemic has helped them feel seen
As both the mother of a childhood cancer survivor and a Curtin University PhD student exploring families’ experiences of childhood cancer, I embarked on a study to understand the pandemic’s effects on kids going through cancer treatment, and their families. Read more: https://theconversation.com/welcome-to-our-world-families-of-children-with-cancer-say-the-pandemic-has-helped-them-feel-seen-while-putting-them-in-peril-175143
- Jan 21
Improving Endocrine Care for Childhood Cancer Survivors
Endocrine issues are some of the most common late effects of cancer treatment. Although 85% of children now survive cancer, studies have shown that 40% to 60% of these children will later develop at least one endocrine complication. Unfortunately, these conditions can go undiagnosed for years, leading to poorer health and lower quality of life. Read more: https://www.newswise.com/articles/improving-endocrine-care-for-childhood-cancer-survivors
- Jan 19
FDA Approves Rare Pediatric Disease Designation for IMX-110 for Rhabdomyosarcoma
Officials with the FDA have approved a Rare Pediatric Disease Designation for IMX-110 for the treatment of pediatric patients with rhabdomyosarcoma. Read more: https://www.pharmacytimes.com/view/fda-approves-rare-pediatric-disease-designation-for-imx-110-for-rhabdomyosarcoma
- Jan 5
Mortality Risk Later in Life May Be Increased in Childhood Leukemia Survivors With Down Syndrome
Patients with Down syndrome have an increased risk for leukemia during childhood, and toxicities related to treatment may be more common in this patient population. Read more: https://www.curetoday.com/view/mortality-risk-later-in-life-may-be-increased-in-childhood-leukemia-survivors-with-down-syndrome